Substance P activates ADAM9 mRNA expression and induces α-secretase-mediated amyloid precursor protein cleavage.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Neuropharmacology

• Publication date

  2012-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.neuropharm.2011.12.025PMID 22244942
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase

  2010cited by this paper
• SP protects cerebellar granule cells against beta-amyloid-induced apoptosis by down-regulation and reduced activity of Kv4 potassium channels.

  2010cited by this paper
• An Overview of APP Processing Enzymes and Products

  2010cited by this paper
• The secretases: enzymes with therapeutic potential in Alzheimer disease

  2010cited by this paper
• Upregulation of the α‐secretase ADAM10 – risk or reason for hope?

  2010influential reference
• ADAM10, the Rate-limiting Protease of Regulated Intramembrane Proteolysis of Notch and Other Proteins, Is Processed by ADAMS-9, ADAMS-15, and the γ-Secretase*

  2009cited by this paper
• The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice.

  2007cited by this paper
• Substance P provides neuroprotection in cerebellar granule cells through Akt and MAPK/Erk activation: evidence for the involvement of the delayed rectifier potassium current.

  2007influential reference
• Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease.

  2007cited by this paper
• The Secreted β-Amyloid Precursor Protein Ectodomain APPsα Is Sufficient to Rescue the Anatomical, Behavioral, and Electrophysiological Abnormalities of APP-Deficient Mice

  2007cited by this paper
• A genomic approach to investigate neuronal apoptosis.

  2006cited by this paper
• [Neuropeptides in Alzheimer's disease].

  2006cited by this paper
• The neuropeptide PACAP promotes ?‐secretase pathway for processing Alzheimer amyloid precursor protein

  2006cited by this paper
• The Disintegrin ADAM9 Indirectly Contributes to the Physiological Processing of Cellular Prion by Modulating ADAM10 Activity*

  2005cited by this paper
• Substance P, Neurokinins A and B, and Synthetic Tachykinin Peptides Protect Mesencephalic Dopaminergic Neurons in Culture via an Activity-Dependent Mechanism

  2005cited by this paper
• Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization.

  2004cited by this paper
• A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model.

  2004cited by this paper
• Neutralization of Transthyretin Reverses the Neuroprotective Effects of Secreted Amyloid Precursor Protein (APP) in APPSw Mice Resulting in Tau Phosphorylation and Loss of Hippocampal Neurons: Support for the Amyloid Hypothesis

  2004cited by this paper
• ADAMs family members as amyloid precursor protein alpha-secretases.

  2003cited by this paper
• Substance P protects spiral ganglion neurons from apoptosis via PKC‐Ca2+‐MAPK/ERK pathways

  2003cited by this paper
• Neuronal fibrillogenesis: amyloid fibrils from primary neuronal cultures impair long-term memory in the crab Chasmagnathus.

  2003influential reference
• ADAMs family members as amyloid precursor protein α‐secretases

  2003cited by this paper
• Mice Lacking the Metalloprotease-Disintegrin MDC9 (ADAM9) Have No Evident Major Abnormalities during Development or Adult Life

  2002cited by this paper
• The Search for α-Secretase and its Potential as a Therapeutic Approach to Alzheimer's Disease

  2002cited by this paper
• Effect of tumor necrosis factor‐α converting enzyme (TACE) and metalloprotease inhibitor on amyloid precursor protein metabolism in human neurons

  2002cited by this paper
• The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer s disease.

  2002cited by this paper
• The Tachykinin Peptide Family

  2002cited by this paper
• A Portrait of Alzheimer Secretases--New Features and Familiar Faces

  2001cited by this paper
• Alzheimer's disease: genes, proteins, and therapy.

  2001cited by this paper
• Cascade of caspase activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis.

  2001cited by this paper
• Protein Kinase C-dependent α-Secretase Competes with β-Secretase for Cleavage of Amyloid-β Precursor Protein in the Trans-Golgi Network*

  2000cited by this paper
• Endogenous APP derivatives oppositely modulate apoptosis through an autocrine loop

  2000cited by this paper
• Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain.

  2000cited by this paper
• Coordinated Expression of β‐Amyloid Precursor Protein and the Putative β‐Secretase BACE and α‐Secretase ADAM10 in Mouse and Human Brain

  2000cited by this paper
• Caspase‐3 Expression by Cerebellar Granule Neurons Is Regulated by Calcium and Cyclic AMP

  1999cited by this paper
• Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein.

  1999cited by this paper
• Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease.

  1999cited by this paper
• Granule neuron DNA damage following deafferentation in adult rats cerebellar cortex: a lesion model.

  1999cited by this paper
• Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity*

  1999cited by this paper
• Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders.

  1998cited by this paper
• Protein Kinase C Activation Increases Release of Secreted Amyloid Precursor Protein without Decreasing Aβ Production in Human Primary Neuron Cultures.

  1998cited by this paper
• Protein kinase C activation increases release of secreted amyloid precursor protein without decreasing Abeta production in human primary neuron cultures.

  1998cited by this paper
• Alterations of substance P metabolism and neuropeptidases in Alzheimer's disease.

  1995cited by this paper
• Muscarinic Regulation of Alzheimer's Disease Amyloid Precursor Protein Secretion and Amyloid β-Protein Production in Human Neuronal NT2N Cells (*)

  1995cited by this paper
• Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury.

  1994cited by this paper
• Development of a method for measuring cell number: application to CNS primary neuronal cultures.

  1994cited by this paper
• Secreted Forms of β-Amyloid Precursor Protein Protect Hippocampal Neurons against Amyloid β-Peptide-Induced Oxidative Injury

  1994cited by this paper
• Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP.

  1993influential reference
• An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P.

  1991cited by this paper
• Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex.

  1991cited by this paper
• Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment.

  1991cited by this paper
• Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides.

  1990cited by this paper
• Neuropeptides in Alzheimer's disease.

  1987cited by this paper

• Substance P mitigates lipopolysaccharide induced cognitive impairment in rats in a dose dependent manner.

  2025influential citation
• Cftr Nominates a Novel Therapeutic Target for Alzheimer's Disease: Evidence from Integrative Omics and In Vitro Validation.

  2025cites this paper
• Recent advances in the molecular signaling pathways of Substance P in Alzheimer's disease: Link to neuroinflammation associated with toll-like receptors.

  2024cites this paper
• Perspective role of Substance P in Amyotrophic Lateral Sclerosis: from neuronal vulnerability to neuroprotection.

  2024cites this paper
• The Double-Edged Effects of Substance P in the Pathology of Alzheimer’s Disease

  2024cites this paper
• A Recent Update on the Role of Estrogen and Progesterone in Alzheimer's Disease

  2024cites this paper
• The Role and Therapeutic Potential of α-secretase in Alzheimer’s Disease

  2023cites this paper
• Involvement of Substance P (SP) and Its Related NK1 Receptor in Primary Sjögren’s Syndrome (pSS) Pathogenesis

  2023cites this paper
• Drug Repurposing Patent Applications July–September 2022

  2022cites this paper
• The therapeutic e cacy of feno brate in nonalcoholic fatty liver disease a meta-analysis of randomized controlled trials

  2021cites this paper
• Circular breakdown of neural networks due to loss of deubiquitinating enzyme (UCH-L1) in gracile axonal dystrophy (gad) mouse

  2021cites this paper
• What Substance P might tell us about the Prognosis and Mechanism of Parkinson's Disease?

  2021cites this paper
• Involvement of Bradykinin Receptor 2 in Nerve Growth Factor Neuroprotective Activity

  2020cites this paper
• The effects of two different intensities of aerobic training protocols on pain and serum neuro-biomarkers in women migraineurs: a randomized controlled trail

  2020cites this paper
• The Formyl Peptide Receptor 2 Regulates Microglial Phenotype Through Immunometabolism: Implications for Alzheimer’s Disease

  2019cites this paper
• Crosstalk between neurokinin receptor signaling and neuroinflammation in neurological disorders

  2019cites this paper
• An outline for the pharmacological effect of icariin in the nervous system

  2019cites this paper
• Beta-amyloid short- and long-term synaptic entanglement.

  2019cites this paper
• Neuropeptides Exert Neuroprotective Effects in Alzheimer's Disease

  2019cites this paper
• Autism genes and the leukocyte transcriptome in autistic toddlers relate to pathogen interactomes, infection and the immune system. A role for excess neurotrophic sAPP&agr; and reduced antimicrobial A&bgr;

  2019cites this paper
• Effects of senescence and angiotensin II on expression and processing of amyloid precursor protein in human cerebral microvascular endothelial cells

  2018cites this paper
• Endocytosis of the tachykinin neuropeptide, neurokinin B, in astrocytes and its role in cellular copper uptake.

  2016cites this paper
• Substance P and Alzheimer's Disease: Emerging Novel Roles.

  2016cites this paper
• Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease.

  2015cites this paper
• Substance P Activates the Wnt Signal Transduction Pathway and Enhances the Differentiation of Mouse Preosteoblastic MC3T3-E1 Cells

  2014cites this paper
• Systemic Administration of Substance P Recovers Beta Amyloid-Induced Cognitive Deficits in Rat: Involvement of Kv Potassium Channels

  2013cites this paper
• Function of Substance P and Substance P Receptor in Exercise

  2013cites this paper
• The tachykinin peptide neurokinin B binds copper forming an unusual [CuII(NKB)2] complex and inhibits copper uptake into 1321N1 astrocytoma cells.

  2013cites this paper
• Different approaches, one target: understanding cellular mechanisms of Parkinson's and Alzheimer's diseases.

  2012cites this paper
• Activation of a-secretases : a novel therapeutic strategy for the treatment of traumatic brain injury ; L'activation des α-sécrétases : une nouvelle stratégie thérapeutique pour le traitement du traumatisme crânien

  2012cites this paper